Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis by Ruscitti, P. et al.
Observational Study Medicine®
OPENPrevalence of type 2 diabetes and impaired
fasting glucose in patients affected by rheumatoid
arthritis
Results from a cross-sectional study
Piero Ruscitti, MDa,
∗
, Francesco Ursini, MD, PhDb, Paola Cipriani, MD, PhDa, Francesco Ciccia, MD, PhDc,
Vasiliki Liakouli, MD, PhDa, Francesco Carubbi, MD, PhDa, Giuliana Guggino, MD, PhDc,
Onorina Berardicurti, MDa, Rosadaniela Grembiale, MDb, Giovanni Triolo, MD, PhDc,
Giovambattista De Sarro, MD, PhDb, Roberto Giacomelli, MD, PhDa
Abstract
Although the better management of rheumatoid arthritis (RA) has signiﬁcantly improved the long-term outcome of affected patients, a
signiﬁcant proportion of these may develop associated comorbidities including cardiometabolic complications. However, it must be
pointed out that a comprehensive cardiometabolic evaluation is still poorly integrated into the management of RA patients, due to a
limited awareness of the problem, a lack of appropriate clinical studies, and optimal strategies for cardiovascular (CV) risk reduction in
RA. In addition, although several studies investigated the possible association between traditional CV risk factors and RA, conﬂicting
results are still available.
On this basis, we planned this cross-sectional study, aimed at investigating the prevalence of type 2 diabetes (T2D) and impaired
fasting glucose (IFG) in RA patients compared with age- and gender- matched control individuals. Furthermore, we analyzed the role
of both traditional and RA-related CV risk factors in predicting T2D and IFG.
We observed an increased prevalence of T2D in RA patients when compared with age- and gender-matched controls. Regression
analyses demonstrated that the presence of high blood pressure (HBP), a longer disease duration, and exposure to corticosteroids
(CCS) were signiﬁcantly associated with an increased likelihood of being classiﬁed as T2D. In addition, we observed an increased
prevalence of IFG in RA patients when compared with age- and gender-matched controls. Regression analyses demonstrated that a
higher body mass index (BMI), the presence of metabolic syndrome (MetS), higher levels of total cholesterol, the presence of
radiographic damage, and higher serum levels of C-reactive protein (CRP) were signiﬁcantly associated with an increased likelihood
of presenting IFG.
In this cross-sectional study, we observed an increased prevalence of T2D and IFG in an Italian cohort of RA patients when
comparedwith age- and gender-matched control individuals. Interestingly, both RA-speciﬁc features, such as disease duration, CCS
exposure, and radiographic damage, and traditional CV risk factors, such as HBP and MetS, were signiﬁcantly associated with
glucose metabolism abnormalities.
Abbreviations: ACPA = anticyclic citrullinated peptide antibodies, ADA = American Diabetes Association, BMI = body mass
index, CCS = corticosteroids, CRP = C-reactive protein, CV = cardiovascular, CVEs = cardiovascular events, DAS28 = Disease
Activity Score including 28 joints, ESR = erythrocyte sedimentation rate, EULAR = European League Against Rheumatism, FPG =
fasting plasma glucose, HAQ = Health Assessment Questionnaire, HBP = high blood pressure, IFG = impaired fasting glucose, IGT
= impaired glucose tolerance, IL = interleukin, MetS = metabolic syndrome, MTX = methotrexate, OGTT = oral glucose tolerance
test, RA= rheumatoid arthritis, RF= rheumatoid factor, SJC= swollen joints count, T2D= type 2 diabetes, TJC= tender joints count,
TNF = tumor necrosis factor, TNFi = TNF inhibitor, VIF = variance inﬂation factor.
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In the last years, the advent of novel therapeutic options including
biologics and small molecules signiﬁcantly improved the outcome
of rheumatoid arthritis (RA) patients and, in particular, their
quality of life.[1–3] The deeper knowledge of pathophysiological
mechanisms, the growing use of a treat-to-target management as
well as the availability of powerful drugs strongly increased the
percentage of patients achieving clinical remission and, conse-
quently, reduced the percentage of those experiencing radio-
graphic progression.[4–7] However, a signiﬁcant proportion of
patients may still develop associated complications and several
studies demonstrated a close association between RA and
cardiometabolic comorbidity.[8–10] To date, during RA, the
leading cause of death are major cardiovascular events (CVEs);
for this reason, growing research efforts are focusing on
improving the management of these nonarticular outcomes.[11,12]
In this context, it has been suggested that a large number of RA
patients manifest traditional cardiovascular (CV) risk factors
such as high blood pressure (HBP) and type 2 diabetes (T2D),
thus worsening their overall CV risk proﬁle.[12,13] In addition, the
rheumatoid pro-inﬂammatory milieu may contribute to this
clinical phenotype and the development of these comorbid-
ities.[14,15] In fact, several well-known RA pathogenic inﬂamma-
tory mediators including interleukin-1b (IL-1b), IL-6, and tumor
necrosis factor (TNF), have been shown to play a pivotal role in
atherosclerosis and metabolic dysregulation.[16] During T2D,
pro-inﬂammatory cytokines contribute to beta-cell dysfunction
and destruction, as observed in bone damage during RA[16–18];
similarly, they participate in the pathophysiology of insulin
resistance.[19] Although these comorbidities frequently occur in
RA patients, cardiometabolic diseases remain still underdiag-
nosed and undertreated in rheumatic patients.[20,21] In addition,
despite speciﬁc European League Against Rheumatism (EULAR)
recommendations,[22,23] a comprehensive evaluation of the
cardiometabolic status in RA patients may be difﬁcult to perform
in the real-life clinical setting and the identiﬁcation of clinical as
well as laboratory biomarkers reﬂecting the CV risk proﬁle is still
awaited.[24–26] Overall, cardiometabolic evaluation is still poorly
integrated into the management of RA patients for multiple
reasons, including a limited awareness of the problem, a lack of
well-designed clinical studies, and optimal strategies for CV risk
estimation and reduction.[27] Although several groups investigat-
ed the possible association between T2D and RA, conﬂicting
results are still available. Moreover, regional differences in T2D
susceptibility may impair the possibility to generalize results from
different geographic areas. In this regards, 2 studies investigated
the prevalence of T2D in Italian RA patients; however, 1 study
evaluated only hospitalized RA patients and the other investigat-
ed the prevalence of occult diabetes.[28,29]
On these bases, we performed this cross-sectional study, aimed
at investigating the prevalence of T2D and impaired fasting
glucose (IFG) in RA patients when compared with age- and
gender-matched controls. Furthermore, we analyzed the role of
both traditional and RA-related CV risk factors in predicting
T2D and IFG.2. Methods
2.1. Study design and patients
In this study, 500 consecutive RA patients attending our
Department during a 5-year period (January 2011–December
2015) were evaluated. As a control group, we recruited 500 age-2and gender-matched consecutive individuals referred to our
Department for musculoskeletal complaints and in whose the
diagnosis of inﬂammatory autoimmune disease, cancer, or other
systemic diseases were excluded after appropriate clinical,
imaging, and laboratory investigations. This population com-
prised a mixed pool of diagnoses including ﬁbromyalgia or other
forms of functional widespread pain (n=84), local or generalized
osteoarthritis (n=227), and other noninﬂammatory painful
musculoskeletal conditions (n=189).
Inclusion criteria were predeﬁned as follows: Adult age (≥18
years); RA classiﬁed according to 2010 American College of
Rheumatology (ACR)/EULAR and/or 1987 ACR criteria.[30,31]
Exclusion criteria were predeﬁned as follows: a past diagnosis of
T2D performed by a physician before the onset of RA; and
treatment with antidiabetic medications (including oral antidia-
betic drugs and insulin) started before the onset of RA.
The local Ethics Committee (Comitato Etico Azienda Sanitaria
Locale 1Avezzano/Sulmona/L’Aquila, L’Aquila, Italy) approved
the study protocol. All investigations have been performed
according to the Good Clinical Practice guidelines and written
informed consent was obtained from all patients, according to the
Declaration of Helsinki.[32]2.2. Deﬁnition of T2D and IFG
Screening for T2D was performed in all patients according to
American Diabetes Association (ADA) 2009 recommenda-
tions.[33] Brieﬂy, patients underwent measurement of plasma
glucose after overnight fasting (fasting plasma glucose, FPG). If
FPG was 100 to 125mg/dL, patients were classiﬁed as IFG.
If FPG ≥126mg/dL, patients were classiﬁed as having T2D.
Abnormal results (≥100mg/dL) were reassessed 1 week later. If
there was inconsistency between the 2 values, a third evaluation
was performed after an additional week. This FPG-based
approach yielded 14 previously unrecognized diagnoses of
T2D. In addition, patients were assigned to the T2D group
independently of FPG values if presenting one or more of
the following criteria: a past diagnosis of T2D performed by a
physician following the diagnosis of RA; and past or current
therapy with antidiabetic medications including oral antidiabetic
drugs and insulin.2.3. Clinical history and disease activity assessment
Relevant data were collected, including demographic character-
istics, smoking habits, RA features and complications (extra-
articular manifestations and/or a past history of RA-related joint
surgery), relevant comorbidities including HBP, metabolic
syndrome (MetS), and obesity, and medications used. The body
mass index (BMI) was used to categorize patients as underweight
(BMI <18.5kg/m2), normal weight (BMI 18.5–25kg/m2),
overweight (BMI 25–30kg/m2), or obese (BMI >30kg/m2).
Radiographic damage was deﬁned as the presence of at least one
marginal erosion on a previously performed hand radiography.
Treatment details were collected in dichotomic variables,
including methotrexate (MTX), TNF inhibitor (TNFi), or other
biologics. In addition, cumulative exposure to corticosteroids
(CCS)≥450mg prednisone-equivalent during the last 3 years was
recorded as a dichotomic variable.
The Disease Activity Score including 28 joints (DAS28-ESR)
was used to assess disease activity, evaluating the number
of swollen joints (SJC), number of tender joints (TJC), and
erythrocyte sedimentation rate (ESR, mm/h).[34] ESRwas selected
Table 1
Clinical characteristics of the study population.
RA (n=500) Controls (n=500) P
Female gender, n (%) 433 (86.6) 433 (86.6) >.99
Age, years 59.3±13.6 58.3±7.4 .14
Smoking habit, n (%) 171 (34.2) 154 (30.8) .28
Obese, n (%) 119 (23.8) 101 (20.2) .17
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independence of C-reactive protein (CRP), a well-established
cardiometabolic risk factor in the general population,[35] for data
analysis purposes. Functional status was evaluated using the
Health Assessment Questionnaire (HAQ),[36] a patient-reported
outcome widely used to assess the impact of RA on everyday
functioning of patients.MetS, n (%) 150 (30.0) 140 (28.0) .53
HBP, n (%) 192 (38.4) 135 (27.0) <.001
T2D, n (%) 68 (13.6) 42 (8.4) .01
IFG, n (%) 102 (20.4) 62 (12.4) .001
Fasting glucose, mg/dL 91.9±16.5 93.6±20.2 .16
Total cholesterol, mg/dL 195.9±54.9 203.3±40.1 .007
Triglycerides, mg/dL 112.7±38.8 115.8±75.1 .42
RA duration, y 10.1±7.1 — —
RF or ACPA positive, n (%) 351 (70.2) — —
Extra-articular features, n (%) 75 (15.0) — —
Joint surgery, n (%) 35 (7.0) — —
Radiographic damage, n (%) 115 (23.0) — —
DAS28-ESR 4.92±1.00 — —
HAQ 0.92±0.61 — —
ESR, mm/h 20.7±15.0 — —
CRP, mg/L 9.80±15.49 — —
MTX, n (%) 424 (84.8) — —2.4. Laboratory evaluation
Blood samples were obtained for laboratory evaluation after
overnight fasting. Glucose, total cholesterol, and triglycerides
were measured with an automated chemistry analyzer (Cobas
6000/Cobas e411; Roche Diagnostics, Monza, Italy). ESR
was evaluated by capillary photometry (Test 1, Alifax).
High-sensitivity CRP was measured by immunonephelometry
(CardioPhase hsCRP; Siemens Healthcare, Milano, Italy).
Rheumatoid factor (RF) was analyzed by nephelometry (BN II
system; Siemens HealthCare). Anti-cyclic citrullinated peptide
antibodies (ACPAs) were analyzed with a chemiluminescent
immunoassay (Zenit RA CCP; Menarini Diagnostics, Firenze,
Italy).TNFi, n (%) 209 (41.8) — —
Other biologics, n (%) 62 (12.4) — —
Steroids, n (%) 402 (80.4) — —
ACPA= anticyclic citrullinated peptide antibodies, CRP=C-reactive protein, DAS28-ESR=disease
activity score including 28 joints and erythrocyte sedimentation rate, HAQ=health assessment
questionnaire, ESR= erythrocyte sedimentation rate, HBP=high blood pressure, IFG= impaired
fasting glucose, MetS=metabolic syndrome, MTX=methotrexate, RA= rheumatoid arthritis, RF=
rheumatoid factor, T2D= type 2 diabetes, TNFi= tumor necrosis factor inhibitors.2.5. Sample size calculation
For the present study, we calculated a sample size of at least 432
patients for each group with a power of 80% and a conﬁdence
level of 95%. This sample size was calculated in order to detect
a prevalence of T2D of at least 10%, which represents a
conservative estimate based on a previous study reporting the
prevalence of undiagnosed T2D in an Italian RA population.[29]
The estimated prevalence in the control group was set at 5%,
corresponding to the prevalence of T2D in the Italian general
population as reported by the National Institute of Statistics
(ISTAT, www.istat.it/).
2.6. Statistical analysis
Data are expressed as mean± standard deviation or number
(percentage) as appropriate.TheStudent t testwasused tocompare
means for continuous variables. The Fisher exact test was used
to compare proportions for dichotomic variables. Single- and
multiple-logistic regression models were performed in order to
evaluate the contribution of selected variables on the likelihood
of having T2D or IFG. Multicollinearity between independent
variableswas evaluated by using the variance inﬂation factor (VIF)
before entering each value in the regressionmodels. AP value<.05
was considered statistically signiﬁcant. All tests were 2-tailed.
The Statistics Package for Social Sciences (SPSS for Windows,
version 17.0; SPSS Inc., Chicago, IL) was used for all analyses.3. Results
3.1. Clinical characteristics
In this study, we evaluated 500 consecutive RA patients, classiﬁed
according to the 2010 ACR/EULAR and/or 1987 ACR Criteria,
and 500 age- and gender-matched controls. The clinical
characteristics of these patients are summarized in Table 1.
The majority of RA patients (70.2%) showed a seropositive
disease with a mean duration of 10.1±7.1 years. The presence of
extra-articular manifestations was observed in 15% of patients
and 7% underwent RA-related joint surgery. The most common
synthetic and biologic disease-modifying antirheumatic drugs3(DMARDs) administered wereMTX and TNFis, respectively. As
expected, a large percentage of RA patients were exposed to CCS
(80.4%). No signiﬁcant differences were observed in smoking
habits, serum levels of total cholesterol and triglycerides, the
percentageofobesepatients, andofpatients affectedbyMetSwhen
comparing RA patients and controls. Moreover, a signiﬁcantly
higher percentage of RA patients was affected by HBP (38.4% vs
27%, P< .001). Table 2 compares the most relevant variables
between the 3 evaluated groups (RA, RA/IFG, RA/T2D).3.2. Prevalence and predictors of T2D
In our study, although FPG did not statistically differ between the
evaluated groups, we observed an increased prevalence of T2D in
RA patients when compared with age- and gender-matched
controls (13.6% vs 8.4%, P= .01). Single- and multiple-logistic
regression models were performed in order to evaluate the
contribution of RA-speciﬁc and traditional CV risk factors on
the likelihood of having T2D in RA patients (Table 3). The
multivariate analysis demonstrated that the presence of HBP, a
longer disease duration, and the treatment with CCS were
signiﬁcantly associated with an increased likelihood of being
classiﬁed as T2D. In particular, the presence of HBP was
associated with 1.77-fold higher risk of having T2D [odds ratio
(OR)=1.77, 95% conﬁdence interval (95% CI) 1.05–3.05,
P= .033]. A 1-year increase of disease duration was associated
with 1.09-fold higher risk of having T2D (OR=1.09, 95% CI:
1.02–1.13, P< .001). The Exposure to CCS was associated with
5.87-fold higher risk of having T2D (OR=5.87, 95% CI
1.23–7.33, P= .015). The logistic regression model was statisti-
cally signiﬁcant (x2=36.08, P< .001).
Table 3
Univariate regression analyses of predictors of T2D.
Univariate analyses Multivariate analysis
OR 95% CI P OR 95% CI P
Gender 0.59 0.24–1.42 .24
Age 1.01 0.99– 1.02 .56
Smoke 0.71 0.40–1.25 .24
BMI 1.13 0.83–1.54 .44
MetS 0.68 0.38–1.24 .21
HBP 1.86 1.11–3.11 .02
∗
1.77 1.05–3.05 .033
∗
Total cholesterol 0.99 0.99–1.00 .32
Triglycerides 0.99 0.99–1.00 .74
RA duration 1.09 1.05–1.13 <.001
∗
1.09 1.02–1.13 <.001
∗
FR or ACPA positive 0.75 0.43–1.28 .29
Extra-articular features 1.11 0.55–2.23 .77
Joint surgery 0.58 0.17–1.94 .37
Radiographic damage 0.68 0.35–1.32 .26
DAS28-ESR 0.80 0.62–1.04 .10
HAQ 0.93 0.61–1.43 .76
ESR 1.00 0.98–1.02 .97
CRP 1.01 0.99–1.02 .17
MTX 1.63 0.72–3.72 .24
TNFi 1.28 0.77–2.14 .34
Other biologics 0.40 0.14–1.15 .09
Corticosteroids 2.77 1.16–6.60 .02
∗
5.87 1.23–7.33 .015
∗
ACPA=anti-cyclic citrullinated peptide antibodies, BMI=body mass index, CRP=C reactive protein, DAS28-ESR=disease activity score including 28 joints and erythrocyte sedimentation rate, ESR=
erythrocyte sedimentation rate, HAQ=health assessment questionnaire, HBP=high blood pressure, IFG= impaired fasting glucose, MetS=metabolic syndrome, MTX=methotrexate, RA= rheumatoid arthritis,
RF= rheumatoid factor, T2D= type 2 diabetes, TNFi= tumor necrosis factor inhibitors.
∗
Indicates statistically signiﬁcant result.
Table 2
Clinical characteristics of RA patients with T2D or with IFG and RA patients without T2D and IFG.
RA† RA/T2D‡ RA vs RA/T2D P RA/IFGx RA vs RA/IFG P
Female gender, n (%) 281 (85%) 61 (89.7%) .23 90 (88%) .59
Age, y 59.2±13.7 60.1±13.5 .71 64.1±12.6 .43
Smoking habit, n (%) 113 (34.2%) 27 (39.7%) .27 29 (28.4%) .19
Obese, n (%) 35 (10.6%) 16 (23.5%) .036
∗
3 (2.9%) .04
∗
MetS, n (%) 80 (24.2%) 16 (23.6%) .21 54 (52.9%) <.001
∗
HBP, n (%) 107 (32.4%) 30 (44.1%) <.001
∗
55 (53.9%) <.001
∗
Fasting glucose, mg/dL 89.6±14.1 108.7±22.1 <.001
∗
107.5±6.3 <.001
∗
Total cholesterol, mg/dL 195.9±56.1 188.1±44.2 <.001
∗
223.9±41.6 <.001
∗
Triglycerides, mg/dL 116.1±51.1 101.1±41.2 .98 132.9±55.3 <.001
∗
RA duration, y 10.4±7.01 9.7 – 8.7 .44 12.3±6.3 .027
∗
RF and/or ACPA positive, n (%) 236 (71.5%) 40 (58.8%) .017
∗
79 (77%) .11
Extra-articular features, n (%) 47 (14.2%) 14 (20.6%) .10 14 (13.7%) .69
Joint surgery, n (%) 47 (7.3%) 7 (10.3%) .25 4 (3.9%) .17
Radiographic damage, n (%) 57 (17.3%) 12 (17.6%) .26 46 (45.1%) <.001
∗
DAS28-ESR 4.9±0.9 4.7±1.2 .121 5.2±1.0 .29
HAQ 0.9±0.6 0.9±0.6 .90 1.0±0.5 .018
∗
ESR, mm/h 20.9±14.6 20.7 – 17.3 .038
∗
24.4±17.2 .88
CRP, mg/L 9.4±12.7 12.4±27.6 .004
∗
13.8±17.1 .87
MTX, n (%) 272 (82.4%) 61 (89.7) .24 91 (89.2%) .17
TNFi, n (%) 132 (40%) 32 (57.1%) .34 45 (44.1%) .59
Other biologics, n (%) 42 (12.7%) 4 (5.9%) .79 16 (15.7%) .25
Steroids, n (%) 256 (77.6%) 62 (91.2%) .017
∗
84 (82.2%) .59
ACPA=anti-cyclic citrullinated peptide antibodies, BMI=body mass index, CRP=C reactive protein, DAS28-ESR=disease activity score including 28 joints and erythrocyte sedimentation rate, ESR=
erythrocyte sedimentation rate, HAQ=health assessment questionnaire, HBP=high blood pressure, IFG= impaired fasting glucose, MetS=metabolic syndrome, MTX=methotrexate, RA= rheumatoid arthritis,
RF= rheumatoid factor, T2D= type 2 diabetes, TNFi= tumor necrosis factor inhibitors.
∗
Indicates statistically signiﬁcant result.
† Indicates RA patients without T2D and IFG.
‡ Indicates RA patients with T2D.
x Indicates RA patients with IFG.
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Table 4
Univariate regression analyses of predictors of IFG.
Univariate analyses Multivariate analysis
OR 95% CI P OR 95% CI P
Gender 0.83 0.43–1.62 .59
Age 1.04 1.02–1.05 <.001
∗
1.01 0.99–1.03 .39
Smoke 1.18 0.75– 1.85 .48
BMI 2.26 1.71–2.97 <.001
∗
2.36 1.71–3.26 <.001
∗
MetS 3.54 2.25–5.56 <.001
∗
1.87 1.03–3.43 .041
∗
HBP 0.94 0.60–1.45 .79
Total cholesterol 1.01 1.00–1.01 <.001
∗
1.01 1.004–1.016 .002
∗
Triglycerides 1.01 1.00–1.02 .001
∗
1.002 0.996–1.008 .43
RA duration 1.03 0.99–1.06 .07
FR or ACPA positive 1.49 0.90–2.46 .12
Extra-articular features 0.88 0.47–1.64 .69
Joint surgery 0.35 0.10–1.15 .08
Radiographic damage 3.90 2.44–6.24 <.001
∗
3.49 1.97–6.18 <.001
∗
DAS28-ESR 1.38 1.11–1.71 .004
∗
1.04 0.79–1.38 .78
HAQ 1.35 0.95–1.90 .09
ESR 1.02 1.00–1.03 .005
∗
1.00 0.98–1.02 .98
CRP 1.02 1.00–1.03 .01
∗
1.02 1.001–1.034 .02
∗
MTX 1.59 0.80–3.14 .18
TNFi 1.13 0.73–1.74 .60
Other biologics 1.42 0.77–2.63 .26
Corticosteroids 1.16 0.66–2.04 .61
ACPA=anti-cyclic citrullinated peptide antibodies, BMI=body mass index, CRP=C reactive protein, DAS28-ESR=disease activity score including 28 joints and erythrocyte sedimentation rate, ESR=
erythrocyte sedimentation rate, HAQ=health assessment questionnaire, HBP=high blood pressure, IFG= impaired fasting glucose, MetS=metabolic syndrome, MTX=methotrexate, RA= rheumatoid arthritis,
RF= rheumatoid factor, T2D= type 2 diabetes, TNFi=Tumor necrosis factor inhibitors.
∗
Indicates statistically signiﬁcant result.
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Similar to T2D prevalence, we observed an increased presence of
IFG in RA patients when compared with age- and gender-
matched controls (20.4% vs 12.4%, P= .001). Single- and
multiple-logistic regression models were performed in order to
evaluate the contribution of RA-speciﬁc and traditional CV risk
factors on the likelihood of having IFG in RA patients (Table 4).
The multivariate analysis demonstrated that a higher BMI, the
presence of MetS, higher levels of total cholesterol, the presence
of radiographic damage, and higher serum levels of CRP were
signiﬁcantly associated with an increased likelihood of showing
IFG, in RA patients. Increasing BMI was associated with 2.36-
fold higher risk of IFG (OR=2.36, 95%CI 1.71–3.26, P< .001),
the presence of MetS with 1.87-fold higher risk (OR=1.87, 95%
CI 1.03–3.43, P= .041), and an increase of 1mg/dL of serum
levels of total cholesterol with 1.01-fold higher risk (OR=1.01,
95% CI 1.004–1.016, P= .002). The presence of radiographic
damage was associated with 3.49-fold higher risk of showing
IFG (OR=3.49, 95% CI 1.97–6.18, P< .001) and an increase
of 1mg/L of serum levels of CRP with 1.02-fold higher risk
(OR=1.02, 95% CI 1.001–1.034, P= .02). In this multivariate
model, the serum levels of triglycerides, increasing ESR, and
disease activity did not seem to be associated with the presence of
IFG. The logistic regression model was statistically signiﬁcant
(x2=103.48, P< .001).
4. Discussion
In this cross-sectional study, we observed an increased prevalence
of T2D and IFG in an Italian cohort of RA patients when
compared with age- and gender-matched control individuals.
Interestingly, both RA-related features—disease duration, CCS
exposure, and radiographic damage—and traditional CV risk5factors, such as HBP andMetS, were signiﬁcantly associated with
glucose metabolism abnormalities.
In our cohort, we observed an increased percentage of RA
patients affected by comorbid T2Dwhen compared with controls
and with the ﬁgures reported for Italian general population
(ISTAT, www.istat.it/), conﬁrming what was suggested in a
recent meta-analysis.[37] Compared with previously published
cohorts, our study has the major advantage of being speciﬁcally
designed and adequately powered, whereas the results of the
currently available literature derive from secondary outcomes
and/or poor quality studies.[38,39] For this reason, to our
knowledge, our study represents the most accurate estimate of
the prevalence of T2D in an Italian RA cohort. The geographic
variation of T2D prevalence, indeed, may avoid to generalize
data from studies carried out in different countries and national
estimates are needed in order to account for genetic, dietary, and
lifestyle inﬂuences on T2D risk. In our study, the presence of
HBP, a longer disease duration, and the exposure to CCS were
signiﬁcant predictors of having T2D. It is alreadywell known that
HBP represents an independent risk factor for T2D in the general
population.[40] We also observed that a longer disease duration
and the exposure to CCS were signiﬁcantly associated with T2D.
Although conﬂicting results are available in literature concerning
the association between disease duration and cardiometabolic
comorbidities,[14,15,41] according to our results, RA duration
seems to be a strong predictor of T2D. To explain this
association, patients with longer RA duration are more likely
to have increased cumulative joint damage and functional
disability due to longstanding inﬂammatory process, leading to
an increased physical inactivity that, in turn, might exert a
detrimental effect on glucose metabolism.[42,43] In addition,
longer RA duration may be associated with a sustained exposure
to drugs with a well-recognized diabetogenic effect[44] and this is
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large percentage of patients was exposed to CCS, another
signiﬁcant predictor of T2D in our analysis. Conversely, some
well-recognized T2D risk factors did not associate with T2D in
our cohort. In particular, we did not observe any signiﬁcant
correlation between obesity and T2D in regression analysis; this
result, however, must be interpreted in the light of the recent
understanding of the impact of RA on body composition that
questions the reliability of this measure in describing the
cardiometabolic risk in RA setting.[45,46]
In addition, we observed a higher percentage of patients
displaying IFG in RA patients when compared with controls,
conﬁrming the available literature.[29,47] IFG is a transitional
abnormality during the natural history of T2D and may
theoretically represent a powerful, inexpensive tool for cardio-
metabolic risk stratiﬁcation. In fact, differently from impaired
glucose tolerance (IGT), requiring the oral glucose tolerance test
(OGTT) to be diagnosed, IFG may be easily identiﬁed with a
simple FPG measurement.[48,49] However, to date, no study
conﬁrmed the predictive role of IFG in RA patients. Furthermore,
we observed that a higher BMI, the presence of MetS, as well as a
higher serum level of total cholesterol were signiﬁcantly
associated with IFG, conﬁrming the well-known role of
traditional CV risk factors in this context. Interestingly, the
presence of radiographic damage and a higher serum level of CRP
were also signiﬁcantly associated with an increased likelihood of
showing IFG, suggesting a possible concurrent role of the
rheumatoid inﬂammatory process in the pathogenesis of earliest
glucose metabolism abnormalities.[42] In fact, several lines of
evidence pointed out the link between cardiometabolic comor-
bidities and RA, and the inﬂammatory process may modulate the
pro-atherogenic metabolic effects observed in RA.[50,51]
Taking together the results of our study, it is possible to
demonstrate a subset of RA patients characterized by glucose
metabolism derangement that, at least theoretically, may be
intercepted by some drugs currently used in RA with preliminary
evidence of efﬁcacy in T2D.[52–55] In this setting, targeting RA
pathophysiology with molecules whose therapeutic effect may
extend beyond the joints inﬂammation may be an interesting
clinical progress in managing RA patients.[56–58]
Despite our study is speciﬁcally designed and powered to
evaluate the prevalence of T2D, different limitations may be
recognized as regularly observed in cross-sectional studies. In
addition, it must be pointed out that, given the observational
design of our study and the lack of treatment randomization, the
possible association between treatments and different outcomes
cannot be uniquely ascertained.[59,60] Moreover, we did not
perform OGTT, the only procedure recognizing the presence of
IGT, and thus we probably misclassiﬁed a small subset of IGT
patients as normal, relying only on the absence of T2D and IFG.
However, OGTT is a complex and time-consuming procedure
and may expose the patients to some side events.[61] Another
potential limitation of our study is the lack of testing for glutamic
acid decarboxylase autoantibodies (GADA), in order to exclude
the possible diagnosis of latent autoimmune diabetes in adults
(LADA), an immune-mediated form of diabetes similar to T1D
but characterized by an onset in adult age (<50 years).[62] Other
features of LADA are genetic susceptibility, signiﬁcant geograph-
ic differences in epidemiology, and a decline in its incidence with
increasing age.[62] However, an Italian study demonstrated that
only a small proportion (∼5%) of previously diagnosed T2D
patients had GADA positivity.[63] Moreover, this cohort had a
mean age of∼55 years, that is signiﬁcantly lower than ours (mean6age of T2D patients in our study: 60±13.5 years). Therefore, we
can hypothesize of having misclassiﬁed only 3 patients, with a
marginal impact on overall study results.
Finally, the control group comprised a large proportion of
osteoarthritis and ﬁbromyalgia patients; both of these diseases
have been associated with an increased rate of comorbid obesity
accounting for the not-statistically signiﬁcant difference in BMI
between patients and controls and the observed prevalence of
T2D in control patients that is higher of what expected in the
general population. This limitation, however, does not affect
signiﬁcantly the reliability of the estimate in the RA cohort, which
remains clearly higher of that expected in unselected Italian
adults.
In conclusion, results from our study may introduce a novel
hypothesis on the interaction between traditional CV risk factors
and inﬂammatory burden in determining T2D in RA; the former
being involved in the earliest phases of glucose metabolism
derangement and providing a permissive milieu for subsequent
development of T2D following the exposure to the high-grade
inﬂammatory process and to diabetogenic drugs in a “double-
hit” fashion. Further studies are still awaited in order to fully
clarify the association between RA and cardiometabolic
comorbidities and to ascertain the optimal therapeutic strategy
for these patients.Acknowledgment
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